%0 Journal Article
%T Monocyte Chemotactic Protein-1 as a Potential Biomarker for Early Anti-Thrombotic Therapy after Ischemic Stroke
%A Hans Worthmann
%A Reinhard Dengler
%A Helmut Schumacher
%A Andreas Schwartz
%A Wolfgang G. Eisert
%A Ralf Lichtinghagen
%A Karin Weissenborn
%J International Journal of Molecular Sciences
%D 2012
%I MDPI AG
%R 10.3390/ijms13078670
%X Inflammation following ischemic brain injury is correlated with adverse outcome. Preclinical studies indicate that treatment with acetylsalicylic acid + extended-release dipyridamole (ASA + ER-DP) has anti-inflammatory and thereby neuroprotective effects by inhibition of monocyte chemotactic protein-1 (MCP-1) expression. We hypothesized that early treatment with ASA + ER-DP will reduce levels of MCP-1 also in patients with ischemic stroke. The EARLY trial randomized patients with ischemic stroke or TIA to either ASA + ER-DP treatment or ASA monotherapy within 24 h following the event. After 7 days, all patients were treated for up to 90 days with ASA + ER-DP. MCP-1 was determined from blood samples taken from 425 patients on admission and day 8. The change in MCP-1 from admission to day 8 did not differ between patients treated with ASA + ER-DP and ASA monotherapy ( p > 0.05). Comparisons within MCP-1 baseline quartiles indicated that patients in the highest quartile (>217¨C973 pg/mL) showed improved outcome at 90 days if treated with ASA + ER-DP in comparison to treatment with ASA alone ( p = 0.004). Our data does not provide any evidence that treatment with ASA + ER-DP lowers MCP-1 in acute stroke patients. However, MCP-1 may be a useful biomarker for deciding on early stroke therapy, as patients with high MCP-1 at baseline appear to benefit from early treatment with ASA + ER-DP.
%K ischemic stroke
%K monocyte chemoattractant protein-1 (MCP-1)
%K antithrombotic therapy
%K neuroprotection
%K dipyridamole
%K acetylsalicylic acid (ASA)
%U http://www.mdpi.com/1422-0067/13/7/8670